1,457 Shares of argenex SE $ARGX Purchased by BG Investment Services LLC

Key Points

• BG Investment Services initiated a position in argenx, purchasing 1,457 shares worth approximately $1.4 million in the third quarter. Institutional investors and hedge funds collectively own 60.32% of the company.
• argenx reported strong quarterly results, with EPS of $7.80 beating estimates of $7.44 and revenue reaching $1.75 billion. The company posted a 31.66% net margin and analysts expect $25.79 in full-year EPS.
• Analyst sentiment remains broadly positive, with the stock holding a “Moderate Buy” consensus and an average price target of $1,142.37, though mixed target revisions and a clinical-development setback are creating near-term uncertainty.

BG Investment Services LLC bought a new position in shares of argenex SE (NASDAQ:ARGX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,457 shares of the company's stock, valued at approximately $1,397,000.

Several other hedge funds have also recently modified their holdings of ARGX. Eastern Bank acquired a new position in argenex in the 2nd quarter valued at $32,000. Whipplewood Advisors LLC acquired a new stake in argenex during the 1st quarter worth $28,000. Axiom Investment Management LLC purchased a new stake in shares of argenex during the first quarter worth $50,000. Mather Group LLC. grew its holdings in shares of argenex by 19.1% during the third quarter. Mather Group LLC. now owns 81 shares of the company's stock worth $78,000 after buying an additional 13 shares in the last quarter. Finally, WPG Advisers LLC grew its holdings in shares of argenex by 17.8% during the first quarter. WPG Advisers LLC now owns 86 shares of the company's stock worth $63,000 after buying an additional 13 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenex Stock Performance

NASDAQ:ARGX opened at $873.71 on Friday. argenex SE has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The company has a 50 day moving average price of $956.62 and a 200 day moving average price of $885.37. The stock has a market capitalization of $54.95 billion, a P/E ratio of 30.49, a PEG ratio of 0.79 and a beta of 0.44.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping the consensus estimate of $7.44 by $0.36. argenex had a return on equity of 35.77% and a net margin of 31.66%. The business had revenue of $1.75 billion during the quarter. Research analysts forecast that argenex SE will post 25.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ARGX shares. Bank of America increased their price target on argenex from $1,016.00 to $1,088.00 and gave the company a "buy" rating in a report on Thursday, July 2nd. Wall Street Zen lowered argenex from a "buy" rating to a "hold" rating in a research note on Sunday. Sanford C. Bernstein reissued a "buy" rating on shares of argenex in a research note on Thursday, October 8th. HC Wainwright upped their target price on argenex from $940.00 to $1,202.00 and gave the company a "buy" rating in a report on Tuesday, August 18th. Finally, Wells Fargo & Company cut their target price on argenex from $1,356.00 to $1,336.00 and set an "overweight" rating for the company in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,142.37.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
• Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
• Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

argenex Profile

argenx SE NASDAQ: ARGX is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx's lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.